Saturday, 31 October 2026European Markets

SAS AB Stock Plummets 19%: What's Behind The Decline?

Loading stream...

(VIANEWS) - SAS AB (SASNO.OL) shares experienced a 19.81% plunge to kr0.04 at 14:46 EST Thursday after previous sessions' upward trend, in keeping with market sentiment as measured by Oslo Bors Benchmark Index_GI's drop by 0.12% after previous gains were posted; at 14:46 ET the stock currently trades 88.97% below its 52-week high of kr0.47.

About SAS AB

SAS AB (publ) is a passenger flight transportation company operating across Nordic and international route networks, as well as offering air cargo services, in-flight sales, ground handling, technical maintenance services and travel-related loyalty programs. Since 1946, they have provided their services from their fleet of 134 aircraft - 16 long-haul, 87 short-haul and 31 regional. Until July 5, 2022 when SAS filed its voluntary petition for reorganization under Chapter 11 with the US Bankruptcy Court for the Southern District of New York.

Yearly Analysis

As an AI language model, I can provide you with the following analysis based on the information you have provided: Yearly Top and Bottom Value SAS AB's stock is currently trading at kr0.04, significantly below its 52-week high of kr0.47. This suggests that it was overvalued in some point in time during 2017. Meanwhile, however, it remains higher than its 52-week low of kr0.01, suggesting recovery may have begun in 2017. Earnings Before Interest, Taxes, Depreciation and Amortization SAS AB's Earnings Before Interest Taxes Depreciation and Amortization is currently negative at -389.12; this suggests it is operating at a loss at present which may concern potential investors; however it's worth keeping in mind that EBITDA should only be seen as one metric when evaluating financial health - it is also important to take other aspects of its performance into consideration as well.

Technical Analysis

SAS AB's stock price has recently traded significantly above both its 50-day moving average of kr0.02 and 200-day moving average of kr0.18. This suggests that in the short term it has performed strongly while long term it has underperformed. Volume of 43732400 indicates increased trading activity today in this stock. SAS AB's intraday variation average for the last week, month and quarter was negative 14.05%, positive 2.26% and 7.93%, respectively. Additionally, its highest amplitude of average volatility during those three time frames was 24.43% in each of these categories - 14% (last week), 13.05% in month 1 and 7.93% in quarter 3. Overall, SAS AB's stock has shown mixed signals with short-term performance being positive while longer term results underperforming expectations. Trading activity levels appear high suggesting there may be considerable interest in its shares at present.

Quarter Analysis

This statement indicates that revenue has increased by 12.8% year-on-year to reach 42.04 billion for the past 12 months, which indicates strong revenue generation capabilities of the company compared with last year at this same period. Although investors should take this as an indicator of its financial health, other factors should also be taken into consideration such as profitability, competition and market trends in order to gain a full picture.

Equity Analysis

Earnings per share (EPS) is an indicator of a company's profitability that measures how much earnings each outstanding share generates. At SAS AB, our trailing twelve month EPS stands at kr-0.8 which indicates that we experienced losses totaling this amount over the course of twelve months.

More news about SAS AB (SASNO.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com